Novel indole-2,3-dione-3-oxime derivatives

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 471/04 (2006.01) A61K 31/40 (2006.01) A61K 31/47 (2006.01) A61K 31/535 (2006.01) A61K 31/55 (2006.01) C07D 487/04 (2006.01)

Patent

CA 2238410

The present invention relates to novel indole-2,3-dione-3-oxime derivatives capable of antagonising the effect of excitatory amino acids, such as glutamate. More specifically the novel indole-2,3-dione-3- oxime derivatives of the invention may be described by general formula (I), wherein R3 represents "Het", or a group of formula (II), wherein "Het" represents a saturated or unsaturated, 4 to 7 membered, monocyclic, heterocyclic ring, at least one of R31, R32, and R33 independently represents hydrogen, alkyl, or hydroxyalkyl, and at least one of R31, R32, and R33 independently represents (CH2)nR34; wherein R34 represents hydroxy, carboxy, alkoxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, cycloalkoxycarbonyl, cycloalkyl-alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, CONR35R36, or "Het"; wherein n is 0, 1, 2, or 3; and R5 represents phenyl, naphthyl, thienyl, or pyridyl, all of which may be substituted. "A" represents a ring of five to seven atoms fused with the benzo ring at the positions marked "a" and "b", and formed by the following bivalent radicals: a-NR6-CH2-CH2-b; a-CH2.-NR6-CH2-b; a-CH2-CH2-NR6-b; a-NR6-CH2-CH2-CH2-b; a-CH2-NR6-CH2-CH2-b; a-CH2-CH2-NR6-CH2- b; a-CH2-CH2-CH2-NR6-b; a-NR6-CH2-CH2-CH2-CH2-b; a-CH2-NR6-CH2-CH2-CH2-b; a-CH2-CH2-NR6-CH2-CH2-b; a- CH2-CH2-CH2-NR6-CH2-b; or a-CH2-CH2-CH2-CH2-NR6-b; wherein R6 represents hydrogen, alkyl or CH2CH2OH; or a pharmaceutically acceptable salt thereof.

La présente invention concerne de nouveaux dérivés d'indol-2,3-dion-3-oxime pouvant jouer un rôle antagoniste vis-à-vis d'aminoacides excitateurs, tels que le glutamate. Plus spécifiquement, les nouveaux dérivés d'indol-2,3-dion-3-oxime selon l'invention correspondent à la formule générale (I), dans laquelle: R<3> représente "Het" ou un groupe de la formule (II), où "Het" représente un noyau monocyclique, hétérocyclique, saturé ou insaturé ayant 4 à 7 éléments, au moins un des groupes R<31>, R<32> et R<33> est, indépendamment, un groupe hydrogène, alkyle ou hydroxyalkyle, et au moins un des groupes R<31>, R<32> et R<33> est, indépendamment, un groupe (CH2)nR<34>, R<34> étant un groupe hydroxy, carboxy, alcoxycarbonyle, alcényloxycarbonyle, alkynyloxycarbonyle, cycloalcoxycarbonyle, cycloalkylalcoxycarbonyle, aryloxycarbonyle, aralcoxycarbonyle, CONR<35>R<36>, ou "Het", et n pouvant valoir 0, 1, 2 ou 3; R<5> phényle, naphtyle, thiényle ou pyridyle, chacun de ces groupes pouvant être substitué; "A" représente un noyau de 5 à 7 atomes fusionnés avec le noyau benzo aux positions marquées "a" et "b", et formé par les radicaux bivalents suivants: a-NR<6>-CH2-CH2-b; a-CH2-NR<6>-CH2-b; a-CH2-CH2-NR<6>-b; a-NR<6>-CH2-CH2-CH2-b; a-CH2-NR<6>-CH2-CH2-b; a-CH2-CH2-NR<6>-CH2-b; a-CH2-CH2-CH2-NR<6>-b; a-NR<6>-CH2-CH2-CH2-CH2-b; a-CH2-NR<6>-CH2-CH2-CH2-CH2-b; a-CH2-CH2-NR<6>-CH2-CH2-b; a-CH2-CH2-CH2-NR<6>-CH2-b; ou bien a-CH2-CH2-CH2-CH2-NR<6>-b. Dans ces derniers radicaux R<6> représente hydrogène, alkyle ou CH2CH2OH. L'invention concerne également un sel pharmaceutiquement acceptable de ces nouveaux dérivés.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Novel indole-2,3-dione-3-oxime derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel indole-2,3-dione-3-oxime derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel indole-2,3-dione-3-oxime derivatives will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1422938

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.